Genzyme sees Ceredase/Cerezyme sales of $250 mil. in 1996; plant approval will allow more growth.
GENZYME CEREZYME MANUFACTURING FACILITY WILL ALLOW GROWTH BEYOND $250 MIL. in sales for the company's Ceredase/ Cerezyme Gaucher's disease treatment products, Genzyme CEO Henri Termeer told the Alex. Brown conference in Baltimore. Genzyme expects sales of the alglucerase products, predominantly from placenta-derived Ceredase, to reach $250 mil. this year, Termeer said. The firm's Boston manufacturing facility for recombinant Cerezyme is "in the final phases of review by FDA," Termeer added.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth